GPV02
Pan-E. coli infections (UTIs, neonatal sepsis, diarrhoea)
Pre-clinicalActive
Key Facts
Indication
Pan-E. coli infections (UTIs, neonatal sepsis, diarrhoea)
Phase
Pre-clinical
Status
Active
Company
About GlyProVac
GlyProVac is a Danish private biotech leveraging its proprietary BEMAP platform to discover and develop bacterial vaccines targeting O-linked glycoproteins, a largely untapped reservoir of antigenic targets. Its lead program, GPV02, is a preclinical vaccine candidate with pan-E. coli potential for UTIs, neonatal sepsis, and diarrheal diseases. The company is funded by a mix of private placements, non-dilutive grants including from CARB-X and Horizon Europe, and is advancing its technology through strategic collaborations with academic and industry partners.
View full company profile